All payments made in the preview are in test mode. Read more
Sign in
Back to Atlas
APotentially durableStandard research/education caution
CMP-0133
Approved

Testosterone undecanoate / Andriol

Ergogenic / AAS

Systemic androgen replacement/anabolic effect

Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type
Esterified testosterone
Primary mechanism
Testosterone prodrug; AR agonist; A:A ratio 1:1 baseline
Primary market use
Hypogonadism / androgen replacement

Pharmacology

Molecular weight (Da)
456.71
Oral bioavailability
Oral lymphatic absorption; low/variable and food-dependent
Half-life
Oral ~3-8 h apparent; IM undecanoate ~20-34 d
Route tags
Oral
Evidence level
Approved
Clinical status
Approved
Value-for-money score
7 / 10

Reported protocol signal

No popular protocol verified yet; keep as reference compound until protocol signal is added.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Notes

Route matters: oral undecanoate has variable lymphatic absorption, while IM undecanoate has long depot kinetics.

Educational and organizational assistant matrix. Not medical advice.

BioChrysalis Atlas is an educational, organizational, and tracking asset. It does not provide medical advice, diagnosis, treatment, prescriptions, or individualized dosing instructions. Compound profiles, protocol notes, and dosage fields summarize publicly discussed or source-listed reference patterns and are not recommendations. Consult a qualified healthcare professional before starting, stopping, or modifying any compound, medication, or supplement protocol.

© BioChrysalis · Evolve · Ascend · Transcend